Diovan is an important drug because it is indicated for the treatment of hypertension to lower blood pressure. Its annual sales also exceeded $2 billion. This may sound like a first, but Ranbaxy of India received FDA approval in 2014 to market its generic version of Diovan.
Apart from this generic version of Diovan, Mylan has 284 abbreviated new drug applications (ANDAs) pending FDA approval, which represent $109.2 billion in annual brand sales, according to IMS Health. Out of the pending ANDAs, 44 are potential first-to-file opportunities.
Mylan is a global pharmaceutical company that offers a growing portfolio of over 1,300 generic pharmaceuticals and several brand medications. The company also offers a range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. Currently, Mylan markets its products in roughly 140 countries and territories with a workforce of over 25,000 people.
Shares of Mylan were down 1% at $55.76 in the last two hours of trading Monday. The stock has a consensus analyst price target of $59.75 and a 52-week trading range of $41.97 to $59.60.
Shares of Novartis did not seem to react to Mylan’s announcement and are up less than 1% at $92.45 in afternoon trading. Something else to note is that Novartis has a market cap of $223 billion, compared to Mylan’s market cap of $21 billion. Novartis has a consensus analyst price target of $100.87 and a 52-week trading range of $77.90 to $96.97.
ALSO READ: America’s Most (and Least) Healthy States
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
